The contracting authorities shall enter into framework agreements for pharmaceutical special medicinal products, which are referred to as colony stimulation factors for systematically use in treatment of neutrophilia and reduced occurrence of febrile neutropenia in adults treated with cytotoxic chemo-therapy. For many indications the medicinal products can replace one another's use.